Literature DB >> 11825780

Update on the epidemiology and transmission of Pneumocystis carinii.

Alison Morris1, C Ben Beard, Laurence Huang.   

Abstract

Although Pneumocystis carinii pneumonia is one of the leading causes of morbidity and mortality among patients with the acquired immunodeficiency syndrome, many questions about its epidemiology and transmission remain unanswered. Whereas traditional theory postulates that the disease results from reactivation of latent infection, recent data suggest that active acquisition of infection, either through environmental exposure or person-to-person transmission, may occur. This review summarizes the current state of knowledge about the epidemiology and transmission of P. carinii and reports on evolving techniques that may improve our understanding of this organism in the future.

Entities:  

Mesh:

Year:  2002        PMID: 11825780     DOI: 10.1016/s1286-4579(01)01514-3

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  16 in total

1.  The Pneumocystis meiotic PCRan1p kinase exhibits unique temperature-regulated activity.

Authors:  Joshua W Burgess; Theodore J Kottom; Leah R Villegas; Jeffrey D Lamont; Elizabeth M Baden; Marina Ramirez-Alvarado; Andrew H Limper
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-13       Impact factor: 6.914

Review 2.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

3.  Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA.

Authors:  Jesse Wells; Francis Gigliotti; Patricia J Simpson-Haidaris; Constantine G Haidaris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

4.  FlindersTechnology Associates (FTA) filter paper-based DNA extraction with polymerase chain reaction (PCR) for detection of Pneumocystis jirovecii from respiratory specimens of immunocompromised patients.

Authors:  Surang Nuchprayoon; Wilai Saksirisampant; Siraya Jaijakul; Issarang Nuchprayoon
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

5.  Pneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques.

Authors:  Heather M Kling; Timothy W Shipley; Sangita Patil; Alison Morris; Karen A Norris
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

6.  Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa.

Authors:  Michael Schomaker; Matthias Egger; Mhairi Maskew; Daniela Garone; Hans Prozesky; Christopher J Hoffmann; Andrew Boulle; Lukas Fenner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

Review 7.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

8.  Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa.

Authors:  Lukas Fenner; Stewart E Reid; Matthew P Fox; Daniela Garone; Maureen Wellington; Hans Prozesky; Marcel Zwahlen; Michael Schomaker; Gilles Wandeler; Nzali Kancheya; Andrew Boulle; Robin Wood; German Henostroza; Matthias Egger
Journal:  Trop Med Int Health       Date:  2012-11-30       Impact factor: 2.622

9.  Healthcare worker occupation and immune response to Pneumocystis jirovecii.

Authors:  Renuka Tipirneni; Kieran R Daly; Leah G Jarlsberg; Judy V Koch; Alexandra Swartzman; Brenna M Roth; Peter D Walzer; Laurence Huang
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

10.  Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study.

Authors:  Elodie Senggen Manoloff; Patrick Francioli; Patrick Taffé; Guy Van Melle; Jacques Bille; Philippe M Hauser
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.